<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919567</url>
  </required_header>
  <id_info>
    <org_study_id>201012095RC</org_study_id>
    <nct_id>NCT01919567</nct_id>
  </id_info>
  <brief_title>Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer.</brief_title>
  <official_title>Observational Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using SOX-9 Inhibitor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the
      Treatment of Oral Cancer Using SOX-9 Inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To find out if there is prognostic value which to the performance of SOX-9 of oral cancer in
      Taiwan and provide some reference for future treatment.

      We anticipate to enroll 40 persons with normal oral mucosa, 65 persons with oral dysplasia
      and 150 persons with oral cancer and collect the tissue which was stained for pathological
      sections over a 3 year period.

      We also collect the blood and saliva samples from patients and the results along with
      patient-specific information such as tumor phases, tumor size, lymph node metastasis, cancer
      metastasis, prognosis and betel nut chewing, smoking and drinking habits and other parameters
      are statistically analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Carcinogenesis of SOX-9</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Carcinogenesis</condition>
  <condition>Oral Cancer</condition>
  <arm_group>
    <arm_group_label>Normal team</arm_group_label>
    <description>Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.
Subjects must:
Should have a blood exam (20ml) before the surgery.
Site staff must:
Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral dysplasia</arm_group_label>
    <description>Subjects who are diagnosed with dysplasia of oral cavity.
Subjects must:
Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
Before the surgery site staff must:
Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.
Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral cancer</arm_group_label>
    <description>Subjects who suffer from oral cancer.
Subjects must:
Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
Before the surgery site staff must:
Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue, serum, saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Medical center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dysplasia or cancer of the oral cavity.

        Exclusion Criteria:

          -  pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin-Jung Cheng, DDS, MS, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Shin-Jung Cheng, DDS, MS, PhD</last_name>
    <phone>+886 2 29251733</phone>
    <phone_ext>67509</phone_ext>
    <email>sjcheng56@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital research Ethics Committee</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin-Jung Cheng, DDS, MS, PhD</last_name>
      <phone>+886 2 29251733</phone>
      <phone_ext>67509</phone_ext>
      <email>sjcheng56@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Shin-Jung Cheng, DDS, MS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E, Juste D, Samuels HH. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene. 2002 Nov 7;21(51):7850-60.</citation>
    <PMID>12420222</PMID>
  </reference>
  <reference>
    <citation>Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, Sanchez-Carbayo M. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer. 2008 Jan 29;98(2):466-73. Epub 2007 Dec 18.</citation>
    <PMID>18087279</PMID>
  </reference>
  <reference>
    <citation>Alvarez-Medina R, Le Dreau G, Ros M, Martí E. Hedgehog activation is required upstream of Wnt signalling to control neural progenitor proliferation. Development. 2009 Oct;136(19):3301-9. doi: 10.1242/dev.041772.</citation>
    <PMID>19736325</PMID>
  </reference>
  <reference>
    <citation>Bien-Willner GA, Stankiewicz P, Lupski JR. SOX9cre1, a cis-acting regulatory element located 1.1 Mb upstream of SOX9, mediates its enhancement through the SHH pathway. Hum Mol Genet. 2007 May 15;16(10):1143-56. Epub 2007 Apr 4.</citation>
    <PMID>17409199</PMID>
  </reference>
  <reference>
    <citation>Lü B, Fang Y, Xu J, Wang L, Xu F, Xu E, Huang Q, Lai M. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008 Dec;130(6):897-904. doi: 10.1309/AJCPW1W8GJBQGCNI.</citation>
    <PMID>19019766</PMID>
  </reference>
  <reference>
    <citation>Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene. 2004 Jun 3;23(26):4584-93.</citation>
    <PMID>15077158</PMID>
  </reference>
  <reference>
    <citation>Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP, Yuan X. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008 Mar 15;68(6):1625-30. doi: 10.1158/0008-5472.CAN-07-5915.</citation>
    <PMID>18339840</PMID>
  </reference>
  <reference>
    <citation>Jay P, Berta P, Blache P. Expression of the carcinoembryonic antigen gene is inhibited by SOX9 in human colon carcinoma cells. Cancer Res. 2005 Mar 15;65(6):2193-8.</citation>
    <PMID>15781631</PMID>
  </reference>
  <reference>
    <citation>Knower KC, Kelly S, Harley VR. Turning on the male--SRY, SOX9 and sex determination in mammals. Cytogenet Genome Res. 2003;101(3-4):185-98. Review.</citation>
    <PMID>14684982</PMID>
  </reference>
  <reference>
    <citation>Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M, Nohno T. Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. Mol Cancer. 2007 Oct 9;6:62.</citation>
    <PMID>17922924</PMID>
  </reference>
  <reference>
    <citation>Mertin S, McDowall SG, Harley VR. The DNA-binding specificity of SOX9 and other SOX proteins. Nucleic Acids Res. 1999 Mar 1;27(5):1359-64.</citation>
    <PMID>9973626</PMID>
  </reference>
  <reference>
    <citation>Murata M, Iwao K, Miyoshi Y, Nagasawa Y, Yabu M, Himeno S, Imanishi K, Ohsawa M, Wada H, Tominaga S, Shimano T, Kobayashi T, Nakamura Y. Activation of the beta-catenin gene by interstitial deletions involving exon 3 as an early event in colorectal tumorigenesis. Cancer Lett. 2000 Oct 16;159(1):73-8.</citation>
    <PMID>10974408</PMID>
  </reference>
  <reference>
    <citation>Fracalossi AC, Silva Mde S, Oshima CT, Ribeiro DA. Wnt/beta-catenin signalling pathway following rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. Exp Mol Pathol. 2010 Feb;88(1):176-83. doi: 10.1016/j.yexmp.2009.11.004. Epub 2009 Nov 17.</citation>
    <PMID>19931241</PMID>
  </reference>
  <reference>
    <citation>de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP. Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck. 2010 Mar;32(3):357-67. doi: 10.1002/hed.21193.</citation>
    <PMID>19644932</PMID>
  </reference>
  <reference>
    <citation>Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004 Jul 5;166(1):37-47.</citation>
    <PMID>15240568</PMID>
  </reference>
  <reference>
    <citation>Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol. 2009 Apr-May;45(4-5):301-8. doi: 10.1016/j.oraloncology.2009.01.004. Epub 2009 Feb 26. Review.</citation>
    <PMID>19249237</PMID>
  </reference>
  <reference>
    <citation>Supić G, Kozomara R, Branković-Magić M, Jović N, Magić Z. Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol. 2009 Dec;45(12):1051-7. doi: 10.1016/j.oraloncology.2009.07.007. Epub 2009 Aug 8.</citation>
    <PMID>19665921</PMID>
  </reference>
  <reference>
    <citation>Vidal VP, Ortonne N, Schedl A. SOX9 expression is a general marker of basal cell carcinoma and adnexal-related neoplasms. J Cutan Pathol. 2008 Apr;35(4):373-9. doi: 10.1111/j.1600-0560.2007.00815.x.</citation>
    <PMID>18333897</PMID>
  </reference>
  <reference>
    <citation>Koopman P, Bullejos M, Bowles J. Regulation of male sexual development by Sry and Sox9. J Exp Zool. 2001 Sep 15;290(5):463-74. Review.</citation>
    <PMID>11555853</PMID>
  </reference>
  <reference>
    <citation>Jiang SS, Fang WT, Hou YH, Huang SF, Yen BL, Chang JL, Li SM, Liu HP, Liu YL, Huang CT, Li YW, Jang TH, Chan SH, Yang SJ, Hsiung CA, Wu CW, Wang LH, Chang IS. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 2010 Sep 1;16(17):4363-73. doi: 10.1158/1078-0432.CCR-10-0138. Epub 2010 Jul 22.</citation>
    <PMID>20651055</PMID>
  </reference>
  <reference>
    <citation>Harley VR, Clarkson MJ, Argentaro A. The molecular action and regulation of the testis-determining factors, SRY (sex-determining region on the Y chromosome) and SOX9 [SRY-related high-mobility group (HMG) box 9]. Endocr Rev. 2003 Aug;24(4):466-87. Review.</citation>
    <PMID>12920151</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>December 8, 2013</last_update_submitted>
  <last_update_submitted_qc>December 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SOX-9</keyword>
  <keyword>Oral cancer</keyword>
  <keyword>arecoline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
    <mesh_term>Carcinogenesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

